Erlotinib prescribing for the second-line treatment of non-small cell lung cancer (NSCLC): The effect of National Institute for Health and Clinical Excellence (NICE) Technology Appraisal 162 (TA162)

✍ Scribed by Banner, R.; Button, M.R.; Hanna, L.; Brewster, A.E.; Tanguay, J.; Stevens, R.; Lester, J.F.

• Book ID: 118574531
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 39 KB
• Volume: 67
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(10)70017-9